Longeveron (LGVN) Expected to Announce Quarterly Earnings on Tuesday

Longeveron (NASDAQ:LGVNGet Free Report) is expected to release its earnings data before the market opens on Tuesday, February 25th. Analysts expect Longeveron to post earnings of ($0.36) per share for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

Longeveron Trading Down 4.9 %

Shares of LGVN opened at $1.56 on Friday. The company has a market capitalization of $23.15 million, a PE ratio of -0.25 and a beta of 0.36. Longeveron has a 12 month low of $0.77 and a 12 month high of $6.40. The stock’s 50-day moving average price is $1.69 and its two-hundred day moving average price is $1.95.

Analyst Upgrades and Downgrades

Several brokerages have commented on LGVN. Roth Capital raised Longeveron to a “strong-buy” rating in a report on Thursday, December 5th. Roth Mkm began coverage on Longeveron in a report on Friday, December 6th. They set a “buy” rating and a $10.00 target price on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Longeveron in a report on Monday, November 25th.

Get Our Latest Stock Analysis on LGVN

About Longeveron

(Get Free Report)

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.

Read More

Earnings History for Longeveron (NASDAQ:LGVN)

Receive News & Ratings for Longeveron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Longeveron and related companies with MarketBeat.com's FREE daily email newsletter.